Systematic review and meta-analysis on the safety of dalbavancin

References

• Dalmastri C, Gastaldo L, Marcone GL, et al. Classification of nonomuraea sp. atcc 39727, an actinomycete that produces the glycopeptide antibiotic a40926, as nonomuraea gerenzanensis sp. nov. Int J Syst Evol Microbiol. 2016 Feb;66(2):912–921.
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Jones RN. Multicenter evaluation of the in vitro activity of dalbavancin tested against staphylococci and streptococci in 5 European countries: results from the DECIDE surveillance program (2007). Diagn Microbiol Infect Dis. 2009 Jun;64(2):177–184.
   PubMed Web of Science ®Google Scholar
• Biedenbach DJ, Ross JE, Fritsche TR, et al. Activity of dalbavancin tested against staphylococcus spp. and beta-hemolytic streptococcus spp. isolated from 52 geographically diverse medical centers in the United States. J Clin Microbiol. 2007 Mar;45(3):998–1004.
   PubMed Web of Science ®Google Scholar
• Goldstein EJ, Citron DM, Warren YA, et al. In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother. 2006 Aug;50(8):2875–2879.
   PubMed Web of Science ®Google Scholar
• Jones RN, Fritsche TR, Sader HS, et al. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): initial results from an international surveillance protocol. J Chemother. 2005 Dec;17(6):593–600.
   PubMed Web of Science ®Google Scholar
• Streit JM, Fritsche TR, Sader HS, et al. Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. Diagn Microbiol Infect Dis. 2004 Feb;48(2):137–143.
   PubMed Web of Science ®Google Scholar
• Streit JM, Sader HS, Fritsche TR, et al. Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. Diagn Microbiol Infect Dis. 2005 Dec;53(4):307–310.
   PubMed Web of Science ®Google Scholar
• Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005 Feb 1;40(3):374–380.
   PubMed Web of Science ®Google Scholar
• Rappo U, Puttagunta S, Shevchenko V, et al. Dalbavancin for the treatment of osteomyelitis in adult patients: a randomized clinical trial of efficacy and safety. Open Forum Infect Dis. 2019 Jan;6(1): ofy331. 6 https://doi.org/10.1093/ofid/ofy331
   Google Scholar
• Barber KE, Tirmizi A, Finley R, et al. Dalbavancin use for the treatment of methicillin-resistant staphylococcus aureus Pneumonia. J Pharmacol Pharmacother. 2017 Apr-Jun;8(2):77–79.
   PubMed Web of Science ®Google Scholar
• Jones BM, Keedy C, Wynn M. Successful treatment of Enterococcus faecalis bacteremia with dalbavancin as an outpatient in an intravenous drug user. Int J Infect Dis. 2018 Nov;76:4–5.
   PubMed Web of Science ®Google Scholar
• Tobudic S, Forstner C, Burgmann H, et al. Dalbavancin as primary and sequential treatment for gram-positive infective endocarditis: 2-year experience at the general hospital of vienna. Clin Infect Dis. 2018 Aug 16;67(5):795–798.
   PubMed Web of Science ®Google Scholar
• MacGregor RR, Graziani AL. Oral administration of antibiotics: a rational alternative to the parenteral route. Clin Infect Dis. 1997 Mar;24(3):457–467.
   PubMed Web of Science ®Google Scholar
• Krsak M, Morrisette T, Miller M, et al. Advantages of outpatient treatment with long-acting lipoglycopeptides for serious gram-positive infections: a review. Pharmacotherapy. 2020 May;40(5):469–478.
   PubMed Web of Science ®Google Scholar
• Rappo U, Gonzalez PL, Puttagunta S, et al. Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections. J Glob Antimicrob Resist. 2019 Jun;17:60–65.
   PubMed Web of Science ®Google Scholar
• Seltzer E, Dorr MB, Goldstein BP, et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis. 2003 Nov 15;37(10):1298–1303.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014 Jun 5;370(23):2169–2179.
   PubMed Web of Science ®Google Scholar
• Haidich AB. Meta-analysis in medical research. Hippokratia. 2010 Dec;14(Suppl 1):29–37.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Rubio L, Solis Garcia Del Pozo J, Nava E, et al. Interaction between magnesium sulfate and neuromuscular blockers during the perioperative period. A systematic review and meta-analysis. J Clin Anesth. 2016 Nov;34:524–534.
   PubMed Web of Science ®Google Scholar
• Solis-garcia Del Pozo J, Minguez-Minguez S, Pw DG, et al. Rasagiline meta-analysis: a spotlight on clinical safety and adverse events when treating parkinson’s disease. Expert Opin Drug Saf. 2013 Jul;12(4):479–486.
   PubMed Web of Science ®Google Scholar
• Cano-Cuenca N, Je S-GDP, Jordan J. Evidence for the efficacy of latrepirdine (Dimebon) treatment for improvement of cognitive function: a meta-analysis. J Alzheimers Dis. 2014;38(1):155–164.
   PubMed Web of Science ®Google Scholar
• Solis-Garcia Del Pozo J, Mf G, Nava E, et al. A systematic review on the efficacy and safety of IL-6 modulatory drugs in the treatment of COVID-19 patients. Eur Rev Med Pharmacol Sci. 2020 Jul;24(13):7475–7484.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang J, Wang R, et al. Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial infections. J Glob Antimicrob Resist. 2020 Dec;3(24):72–80.
   Google Scholar
• Monteagudo-Martinez N, Solis-Garcia Del Pozo J, Nava E, et al. Acute bacterial skin and skin-structure infections, efficacy of dalbavancin: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2020 Oct;21:1–13.
   Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996 Feb;17(1):1–12.
   PubMedGoogle Scholar
• Higgins JPT GS Cochrane handbook for systematic reviews of interventions version 5.1.0 www.cochrane-handbook.org: The Cochrane Collaboration; 2011.
   Google Scholar
• Jauregui LE, Babazadeh S, Seltzer E, et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis. 2005 Nov 15;41(10):1407–1415.
   PubMed Web of Science ®Google Scholar
• Dunne MW, Puttagunta S, Giordano P, et al. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016 Mar 1;62(5):545–551.
   PubMed Web of Science ®Google Scholar
• Jagan N, Pendru R, Jyothinath K. Efficacy of dalbavancin and telavancin in the treatment of acute bacterial skin and skin structure infections. Maedica (Bucur). 2018 Sep;13(3):208–212.
   Google Scholar
• McCarthy MW, Keyloun KR, Gillard P, et al. Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the enhance trial. Infect Dis Ther. 2020 Mar;9(1):53–67.
   PubMed Web of Science ®Google Scholar
• Bouza E, Valerio M, Soriano A, et al. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents. 2018 Apr;51(4):571–577.
   PubMed Web of Science ®Google Scholar
• Wunsch S, Krause R, Valentin T, et al. Multicenter clinical experience of real life dalbavancin use in gram-positive infections. Int J Infect Dis. 2019 Apr;81:210–214.
   PubMed Web of Science ®Google Scholar
• Morata L, Cobo J, Fernandez-Sampedro M, et al. Safety and efficacy of prolonged use of dalbavancin in bone and joint infections. Antimicrob Agents Chemother. 2019;63(5):May.
   Web of Science ®Google Scholar
• Bai F, Aldieri C, Cattelan A, et al. Efficacy and safety of dalbavancin in the treatment of acute bacterial skin and skin structure infections (ABSSSIs) and other infections in a real-life setting: data from an Italian observational multicentric study (DALBITA study). Expert Rev Anti Infect Ther. 2020 Dec;18(12):1271–1279.
   PubMed Web of Science ®Google Scholar
• Núñez-Núñez MC-HI, García-Fumero R, Vallejo-Rodríguez I, et al. Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications. Eur J Hosp Pharm. 2020;27(5):2.
   Google Scholar
• Gonzalez PL, Rappo U, Akinapelli K, McGregor JS, et al. Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs.Drugs Context. 2018. Dec 11;7:212559.
   Google Scholar
• Dunne MW, Sahm D, Puttagunta S. Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the discover studies. Ann Clin Microbiol Antimicrob. 2015 Apr;14(1):19.
   PubMed Web of Science ®Google Scholar
• Tobudic S, Forstner C, Burgmann H, et al. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection. Infection. 2019 Dec;47(6):1013–1020.
   PubMed Web of Science ®Google Scholar
• Bork JT, Heil EL, Berry S, et al. Dalbavancin use in vulnerable patients receiving outpatient parenteral antibiotic therapy for invasive gram-positive infections. Infect Dis Ther. 2019 Jun;8(2):171–184.
   PubMed Web of Science ®Google Scholar
• Arrieta-Loitegui MC-TJ, Ortiz-Pérez S, López-Medrano F, et al. Effectiveness, safety and cost analysis of dalbavancin in clinical practice. Eur J Hosp Pharm. 2020. DOI:https://doi.org/10.1136/ejhpharm-2020-002315
   PubMedGoogle Scholar